Tower Research Capital (TRC)’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Tower Research Capital (TRC)’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-186	Closed	-$7.84K	–	5570
2015 Q1	$7K	Buy	186 +105	+130%	+$4.04K	﹤0.01%	3116
2014 Q4	$3K	Sell	81 -20	-20%	-$706	﹤0.01%	3254
2014 Q3	$4K	Sell	101 -1,459	-94%	-$50K	﹤0.01%	3536
2014 Q2	$51K	Buy	1,560 +489	+46%	+$16.7K	0.01%	1291
2014 Q1	$39K	Sell	1,071 -729	-41%	-$26.8K	0.01%	1292
2013 Q4	$69K	Buy	1,800 +1,500	+500%	+$47.4K	0.01%	1128
2013 Q3	$8K	Buy	+300	New	+$7.11K	﹤0.01%	3404

Other funds holding WX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CGI

Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Tower Research Capital (TRC)'s WX Position: Q2 2015 in Review

Tower Research Capital (TRC) sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q2 2015, closing a stake of 186 shares — an estimated $7.84K sold.

Tower Research Capital (TRC) first reported a position in WX in Q3 2013 and held it in 7 quarters. The position peaked at $69K in Q4 2013. 154 funds tracked by Wall St. Rank hold WX as of Q2 2015.

Tower Research Capital (TRC) reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q2 2015 after selling out during the quarter.
Tower Research Capital (TRC) sold 186 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q2 2015, an estimated $7.84K.
Tower Research Capital (TRC) first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 7 quarters.
Tower Research Capital (TRC)'s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $69K in Q4 2013.
154 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q2 2015.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2015, filed 30 Jul 2015.